Abstract:Introduction: Endothelial dysfunction and arterial inflammation are critically important for cardiovascular diseases such as atherosclerosis. Of major importance, they are among the predominant culprits that promote the transition from stable to vulnerable atheromas. Our pilot studies revealed Disabled Homolog 2 (Dab2) deficiency in endothelial cells (EC) results in endothelial dysfunction. However, the molecular mechanisms that direct Dab2 to combat endothelial dysfunction during atherosclerosis are completely unknown. Hypothesis: Dab2 prevents the progress of atherosclerosis by maintaining EC function and reducing inflammatory factors. Methods and Results: We examined the expression of endothelial Dab2 in human atherosclerosis patients and ApoE -/- mice fed a western diet (WD) for 12 weeks by immunoflurecent co-staining of VE-cadherin and Dab2 and observed drastically reduced Dab2 expression in the endothelium and intima of human fatty streaks and mouse atherosclerotic aortae. Genetic deletion of Dab2 in the endothelium of ApoE -/- mice on a WD for 12 weeks significantly increased atherosclerosis as revealed by Oil Red O staining of aortic roots and arches, suggesting that Dab2 could be a atheroprotective flow-responsive gene. Similar results were found in WT and EC-iDab2KO mice injected with AAv8-PCSK9 virus. RNA-seq of primary mouse aortic ECs (MAECs) isolated from WT and EC-Dab2iKO mice revealed Dab2 deficiency upregulated many inflammatory genes. qRT-PCR confirmed TNF-α and IL-6 were significantly upregulated in Dab2KO MAECs. Additionally, we observed an increase in Dab2 binding to NEMO in the absence of endocytic adapter proteins epsins via co-IP with anti-Dab2 in WT and epsin-deficient DKO MAECs. We also found three Klf4 binding sites present in the Dab2 gene promoter/enhancer and that overexpression of Klf4 upregulated Dab2 expression in a dosage-dependent manner. Conclusions: Our findings indicated the essential role of Dab2 in protecting the atherogenic endothelium by reducing macrophage accumulation and increasing plaque stability in the aortic roots, which may provide new anti-atherosclerotic therapeutics.

Mef2c Protects Against The Development Of Atherosclerosis Via Inhibiting Tlr/Nf-Kappa B Activation

Leukocyte Cell-Derived Chemotaxin 2 Inhibits Development of Atherosclerosis in Mice

Abstract 1681: Haploinsufficiency of MEF2A Increases Risk of Atherosclerosis in Mice

Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/β-catenin signaling

Activation of Nrf2 inhibits atherosclerosis in ApoE-/- mice through suppressing endothelial cell inflammation and lipid peroxidation

The Effects of Myocyte Enhancer Factor 2A Gene on the Proliferation, Migration and Phenotype of Vascular Smooth Muscle Cells.

Role of MEF2C in the Endothelial Cells Derived from Human Induced Pluripotent Stem Cells

Myocyte enhancer factor 2A delays vascular endothelial cell senescence by activating the PI3K/p-Akt/SIRT1 pathway

Cellular Repressor of E1a-Stimulated Genes Inhibits Inflammation to Decrease Atherosclerosis in Apoe(-/-) Mice

MEF2C promotes M1 macrophage polarization and Th1 responses

MEF2C ameliorates learning, memory, and molecular pathological changes in Alzheimer’s disease <italic>in vivo</italic> and<?A3B2 ACK?><italic>in vitro</italic>

CCCTC-binding factor suppresses alpha-2-macroglobulin transcription to improve vascular endothelial cell functions in lower extremity arteriosclerosis obliterans

Abstract 18579: Endocytic Adaptor Protein DAB2 is a Novel Atheroprotective Regulator in Atherosclerosis

MEF2C mediates inhibitory effect of microRNA-214 on cardiomyocyte hypertrophy

Overexpression of Mitofusin 2 Inhibited Oxidized Low-Density Lipoprotein Induced Vascular Smooth Muscle Cell Proliferation and Reduced Atherosclerotic Lesion Formation in Rabbit.

Inhibition of MEF2A prevents hyperglycemia-induced extracellular matrix accumulation by blocking Akt and TGF-β1/Smad activation in cardiac fibroblasts

MEF2A Is the Trigger of Resveratrol Exerting Protection on Vascular Endothelial Cell

Myocyte-specific Enhancer Factor 2C: a Novel Target Gene of Mir-214-3p in Suppressing Angiotensin II-induced Cardiomyocyte Hypertrophy.

Mitofusin 2 Decreases Intracellular Lipids in Macrophages by Regulating Peroxisome Proliferator-Activated Receptor-Γ.

Activation of Nrf2/Are Pathway Protects Endothelial Cells from Oxidant Injury and Inhibits Inflammatory Gene Expression

Role of MEF2 in Cardiac Development and Cardiovascular Diseases